Search Results for “Annual Report” - Page 7

Meet our volunteers: Daniel Summers

Dan found out he had retinitis pigmentosa in February 2022, but he feels it has been “on cards for years”. He said he had “an inkling something was up but never did anything about it: a typical guy I guess!”

Meira GTx announces positive data from phase clinical trial

Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.

Information and support services

Whether you are looking for practical information or emotional support, online, by phone or face-to-face, we’re here to help.

From Lab to Clinical Trial: First Healthy Volunteer Dosed with OCT-980

Octant, a clinical stage drug discovery company, has recently announced the dosing of the first healthy volunteer in their Phase 1a clinical trial of OCT-980 for Rhodopsin-associated autosomal dominant Retinitis Pigmentosa (RHO-adRP).

Completed Research Project Outcomes

The following projects were being funded by Retina UK and have recently come to an end.

A man wearing a red checked shirt standing at a lectern in front of a number of seated people

The Gene Team

Funding from Retina UK has allowed to team to explore the viability of gene therapy as a treatment for RP and related conditions, and build a pipeline of clinical trials.

Slit lamp biomicroscope used in ophthalmology and optometry for detailed eye examinations.

Experimental therapy by Retina UK-funded researchers leads to ‘life changing improvements’

Researchers who received funding from Retina UK have carried out experimental gene therapy that is reported to have led to ‘life changing improvements’ to sight for four children with inherited sight loss.